On this page · 5 sections→
Where the EU money came from
Funding by EU programme. Amounts are Pherecydes Pharma SA's own share of each project, not the project's full budget.
- Horizon 2020€2.4M · 1 project
- FP7 (2007 to 2013)€2.0M · 1 project
Projects
2 EU-funded projects, newest first. Pherecydes Pharma SA led 1 of them as coordinator. Each links to the official record.
- PhagoPRODCoordinator
GMP manufacturing & GLP diagnostic: Towards a personalised phage therapy against antimicrobial resistance
Horizon 2020 · 2018–2021 · Project on CORDIS ↗
€2.4Mtheir share - PHAGOBURNPartner
Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa burn wound infections (Phase I-II clinical trial)
FP7 (2007 to 2013) · 2013–2017 · Project on CORDIS ↗
€2.0Mtheir share
Works most with
Organisations that shared the most EU projects with this one. A good starting list for consortium partners.
Fields it works in
Research fields recorded on its Horizon projects.
- antibiotic resistance
- antibiotics
- bacteriology
- multidrug resistance
- pathology
- pharmaceutical drugs
- virology
Is this your organisation?
Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.
Claim this profile →Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships. Official website ↗